Literature DB >> 18826998

Rate of beta-cell destruction in type 1 diabetes influences the development of diabetic retinopathy: protective effect of residual beta-cell function for more than 10 years.

Koji Nakanishi1, Chizuru Watanabe.   

Abstract

CONTEXT: Although residual beta-cell function delays the onset and progression of diabetic retinopathy in patients with type 1 diabetes, the rate of beta-cell destruction is variable.
OBJECTIVE: The aim of the study was to clarify the influence of the rate of beta-cell destruction on the development and progression of diabetic retinopathy in type 1 diabetes.
DESIGN: We performed a historical cohort study regarding residual beta-cell function and retinopathy.
SETTING: The study was conducted in the outpatient clinic of a general hospital. PATIENTS: A total of 254 patients with type 1 diabetes participated. MAIN OUTCOME MEASURES: Serum C-peptide and fundus findings were evaluated longitudinally.
RESULTS: The cumulative incidence of mild nonproliferative diabetic retinopathy was higher in the patients without detectable beta-cell function than in those with residual beta-cell function at 20, 15, and 10 yr after the onset of diabetes (P = 0.013, P = 0.006, and P = 0.048, respectively), but not at 5 yr after the onset (P = 0.84). There were higher mean glycosylated hemoglobin values during the entire follow-up period in the patients without detectable beta-cell function at 20 and 15 yr after the onset of diabetes (P = 0.030 and P = 0.042, respectively). Positivity for HLA-A24 and -DQA1 03, as well as the acute onset of diabetes, was associated with early beta-cell loss and also with early development of diabetic retinopathy. Cox proportional hazards analysis showed that undetectable beta-cell function at 20, 15, or 10 yr after the onset of diabetes was an independent risk factor for the development of diabetic retinopathy.
CONCLUSIONS: Undetectable beta-cell function within 10 yr of the onset of type 1 diabetes is associated with the earlier occurrence of diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826998     DOI: 10.1210/jc.2008-1209

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Persistent C-peptide levels and microvascular complications in childhood onset type 1 diabetes of long duration.

Authors:  Katherine V Williams; Dorothy J Becker; Trevor J Orchard; Tina Costacou
Journal:  J Diabetes Complications       Date:  2019-05-31       Impact factor: 2.852

Review 2.  Future opportunities in diabetic retinopathy research.

Authors:  Thomas W Gardner; Emily Y Chew
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

Review 3.  Type 1 diabetes: A predictable disease.

Authors:  Kimber M Simmons; Aaron W Michels
Journal:  World J Diabetes       Date:  2015-04-15

Review 4.  Factors determining insulin requirements in women with type 1 diabetes mellitus during pregnancy: a review.

Authors:  Naomi Achong; Harold David McIntyre; Leonie Callaway
Journal:  Obstet Med       Date:  2014-01-17

5.  Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions.

Authors:  Benjamin Udoka Nwosu
Journal:  Eur Med J Diabetes       Date:  2019-03-14

6.  Current clinical state of type 1 diabetes in Saitama prefecture.

Authors:  Yoichi Oikawa; Koshi Hashimoto; Kazuo Hara; Jiro Morimoto; Kazuyuki Namai; Akihiko Tanaka; Satoshi Tanaka; Akira Shimada
Journal:  Diabetol Int       Date:  2021-11-01

7.  Multiparameter screening reveals a role for Na+ channels in cytokine-induced β-cell death.

Authors:  Yu Hsuan Carol Yang; Yury Y Vilin; Michel Roberge; Harley T Kurata; James D Johnson
Journal:  Mol Endocrinol       Date:  2014-01-17

8.  HLA class I and II alleles are associated with microvascular complications of type 1 diabetes.

Authors:  E M Lipner; Y Tomer; J A Noble; M C Monti; J T Lonsdale; B Corso; W C L Stewart; D A Greenberg
Journal:  Hum Immunol       Date:  2013-01-29       Impact factor: 2.850

9.  Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy.

Authors:  Koji Nakanishi; Satoshi Saitoh
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

10.  Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay.

Authors:  Limei Wang; Nicholas Fraser Lovejoy; Denise L Faustman
Journal:  Diabetes Care       Date:  2012-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.